Optimal follow-up schedule for patients taking PCSK9 monoclonal antibodies in a health system: Analysis of specialty pharmacy clinical interventions

CONCLUSION: Patients beyond 1 year of PCSK9 mAb therapy required less clinical pharmacist interventions. Therefore, stable patients receiving a PCSK9 mAb may be considered for less frequent clinical assessments to allow for HSSP growth to nontraditional clinical areas.PMID:38347759 | DOI:10.1093/ajhp/zxae033
Source: American Journal of Health-System Pharmacy : AJHP - Category: Drugs & Pharmacology Authors: Source Type: research